OPTION CARE HEALTH, INC. (OPCH): what the price assumes

In the published model solve dated 2026-Q2, anchored at $23.90, OPTION CARE HEALTH, INC. (OPCH) is priced for -3.5% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/OPCH

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Solve inputs: computed at a 7.6% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.1%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Option Care is a mature, scaled home-infusion provider, and read through that lens the stock is cheap. The methods land near a $51 base against a $21.99 price, and the implied-expectations read actually backs out a slight decline, about minus 4.3% growth, to justify the price. The market is pricing contraction into a business that is still growing.

The depressing factor is identifiable and management calls it temporary. A Stelara biosimilar transition created roughly a 600 basis point revenue drag in Q1 2026 and a gross-profit headwind, and management framed the quarter as the reset with no carryover into 2027.

The balance sheet is manageable. Net debt near $982 million against trailing operating income of $331 million is roughly 3x leverage, with interest coverage above 6x, and operating cash flow guided above $340 million. The thesis is whether the reset is one-time, as management says, or the start of a reimbursement-driven margin grind.

Bull Case

Frame Option Care by its stage, because the trailing numbers read very differently once you do. This is a mature, national home-and-alternate-site infusion provider, the scaled leader in a business that moves expensive drug therapies out of the hospital and into the home and infusion suites. It is not a growth story to be valued on a runway, nor a turnaround; it is a steady, cash-generative platform. And on that basis the stock is inexpensive. The methods center near a $51 base against a $21.99 price (June 27, 2026), and the implied-expectations read requires only that the business avoid a roughly 4% annual decline to justify the price. The market is pricing in shrinkage; the company is not shrinking.

The scale advantage is the durable edge. Option Care's 10-K describes a position that, through "the purchasing power of its national platform," lets the company "negotiate favorable terms and economics, including volume purchase rebates," and notes that its presence "at national, regional and local levels places it in a strong position against existing and potential competitors" (FY2025 10-K, accession 0001014739-26-000008). In a business where drug cost is the largest input, a national buyer with rebate leverage and a coast-to-coast clinical footprint is hard to replicate. That scale is why the company can serve both high-acuity acute therapies and chronic ones across a fragmented payor landscape.

The cash generation is the proof the franchise is healthy beneath the headline. Q1 2026 revenue grew just over 1% to $1.35 billion, held back by a known biosimilar reset rather than by demand weakness, with acute therapy strong. Management guided full-year adjusted EBITDA to $480 to $500 million and operating cash flow above $340 million, the latter representing at least 30% growth in 2026. A scaled provider converting revenue to cash at that rate, with the share count shrinking about 3% a year, is returning value while the market prices a decline that is really a one-time portfolio reset. If acute strength continues and the Stelara drag rolls off as management expects, the earnings power supports a value well above the current price, which is exactly what the methods say.

Bear Case

The bear case is about the external variable with the most leverage on Option Care: reimbursement and drug-pricing policy. The company's revenue is the spread between what it is paid for therapies and what the drugs and care cost, and a large share of that payment comes from government and commercial payors whose rules it does not set. The 10-K notes the business is paid through "government healthcare programs, such as Medicare and Medicaid" and that "pricing benchmarks in the pharmacy industry are periodically published by third parties" and govern reimbursement (FY2025 10-K, accession 0001014739-26-000008). A change in those benchmarks, a Medicare or Medicaid rate cut, or a shift in how high-cost drugs are reimbursed could compress the margin directly, and the current price does not appear to discount a hostile policy turn.

The Stelara episode shows how fast a single drug dynamic can move the numbers, and why the price is skeptical of management's reassurance. The Stelara biosimilar transition created roughly a 600 basis point revenue drag in Q1 2026 and pushed the expected full-year gross-profit headwind to about $55 million. Management called Q1 the reset with no carryover, but the market has heard before that a one-time headwind is contained. The chronic-therapy portfolio is exposed to exactly this kind of drug-mix and biosimilar churn, and the next branded-to-biosimilar transition could create a similar drag the price is not assuming.

The leverage turns these policy and mix risks into equity risk. Net debt sits near $982 million against trailing operating income of $331 million, roughly 3x leverage, with interest coverage above 6x. That is manageable in good times, but a business that loses several points of margin to a reimbursement change or another biosimilar reset would see its coverage and free cash flow compress while it still has to service the debt. The methods say the stock is cheap on normalized earnings, but normalized assumes the reset is one-time and reimbursement holds. If instead the chronic portfolio faces recurring drug-mix headwinds or a policy-driven rate cut, the apparent cheapness is the market correctly pricing a margin grind, not a mispricing. That is the classic shape that keeps a value name cheap.

Valuation

Option Care screens cheap, with the methods clustered above the price. The base estimate is near $51 against a $21.99 price, and the price is justified by the relative-multiple and growth-DCF families, while the earnings-power family calls it expensive. The individual reads spread accordingly: a DCF perpetual growth near $47, relative valuation near $24, and EV/EBITDA relative near $23 sit above or near the price, while the earnings-power and FCF-yield methods land lower, reflecting that on a strict normalized-earnings basis the current depressed margin does not support a high value. The blended picture is a price below most of the methods.

The inversion is the most telling part. With current operating margin around 5.8%, backing out the price requires only an implied operating margin near 0.9% and an implied growth rate of about minus 4.3%. In other words, the price is consistent with the business slowly declining and barely staying profitable. That is a low bar for a scaled, cash-generative infusion leader still posting positive revenue growth and guiding to higher EBITDA and operating cash flow. The reliability flag is ok and the rarity check is within range, so the methods are not flagging the cheapness as an artifact; they are saying the market is pricing pessimism.

The balance sheet sets the risk frame without changing the central estimate. Net debt near $982 million, roughly 3x trailing operating income, with interest coverage above 6x and operating cash flow guided above $340 million, is a manageable load for a steady cash generator but is the channel through which a reimbursement shock would hit equity. The valuation is attractive on normalized numbers, and the reliability of that read depends on the Stelara reset being one-time, as management asserts, and on reimbursement staying stable. Paid at this price, an investor is underwriting that the depressed margin is a temporary trough rather than a new, policy-driven baseline, which is precisely the disagreement the price reflects.

Catalysts

Option Care reported Q1 2026 revenue of $1.35 billion, up just over 1% year over year but about 3.3% below expectations, with acute therapy strength offset by a chronic-therapy reset tied to the Stelara biosimilar transition (Globe and Mail). The Stelara dynamic created roughly a 600 basis point revenue drag and a full-year gross-profit headwind, which management characterized as the reset with no carryover into 2027 (Yahoo Finance).

The catalysts ahead are the roll-off of that headwind and the durability of acute growth. Management lowered full-year 2026 net revenue guidance to $5.675 to $5.775 billion, just over 1% growth at the midpoint, while guiding adjusted EBITDA to $480 to $500 million and operating cash flow above $340 million, at least 30% growth (Motley Fool transcript). Watch three things over the coming quarters: whether revenue growth reaccelerates as the Stelara drag annualizes out, whether acute-therapy momentum continues to offset chronic-mix pressure, and whether operating cash flow tracks toward the 30%-plus growth guide. Confirmation that the reset was one-time, with reaccelerating growth and strong cash conversion, would validate the value case, since the methods sit well above the price. A second biosimilar or reimbursement headwind would confirm the market's pessimism and keep the stock cheap.

Peer Cohorts (Per Segment, With Filing Citations)

Option Care Health (consolidated) (reported)

• BTSG (BrightSpring Health Services, Inc.)
• FY2025 10-K: …by the management selling stockholders in connection with the Secondary Offerings. The Company did not purchase any shares of common stock that were offered in the June 2025 secondary public offering. In connection with the October 2025 secondary public offering, the Company concurrently purchased from the…
• FY2025 10-K: …Additionally, for Seniors and others who require supportive care and activities of daily living support that address social determinants of health, including dietary and nutrition management and cognitive and social engagement, among others, we offer these daily or weekly services. 61 Table of Contents We are…
• AVAH (Aveanna Healthcare Holdings Inc.)
• FY2025 10-K: …home health and hospice services or similar services. If states with such existing laws remove such barriers, we could face increased competition in these states. We may encounter increased competition in the future that could negatively impact patient referrals to us, limit our ability to maintain or increase our…
• FY2025 10-K: 022). 4.2 Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 4.4 to the registration statement on Form S-1 (File No. 333-254981), filed with the SEC on April 28, 2021). 4.3 Amended and Restated Stockholders Agreement (incorporated by reference to Exhibit 4.5 to the registration…
• CHE (CHEMED CORPORATION)
• FY2025 10-K: …are complex and subject to varying interpretation. Compliance with such laws and regulations may be subject to future government review and interpretation. Additionally, the contracts we have with commercial health insurance payors provide for retroactive audit and review of claims. Settlement with third party payors…
• FY2025 10-K: …& Retirement Plan, effective January 1, 2001.*,** 10.17 Third Amendment to Chemed/Roto-Rooter Savings & Retirement Plan, effective December 12, 2001.*,** 10.18 Directors Emeriti Plan.*, 10.19 Chemed Corporation Change in Control Severance Plan, as amended August 3, 2018. 10.20 Chemed Corporation Senior Executive…
• FMS (FRESENIUS MEDICAL CARE AG)
• FY2025 20-F: …​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Segment and corporate information in € K ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Care ​ ​ Care Total Inter-segment ​ ​ ​ ​ ​ ​ ​ ​ Delivery ​ ​ ​ Value-Based Care ​ ​ ​ Enablement ​ ​ ​ Segment ​ ​ ​ eliminations ​ ​ ​ Corporate ​ ​ ​ Total 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenue from healthcare…
• FY2025 20-F: …"Put option liabilities" in the consolidated statements of shareholders' equity, respectively. A deferred tax liability initially established in 2022 (as a result of a remeasurement gain recognized for the transaction) was reversed with the corresponding tax income of $ 38,792 (€ 34,679 ) recognized in the line item…
• DVA (DAVITA INC.)
• FY2025 10-K: …operating income and adjusted operating income for the year ended December 31, 2024 includes foreign currency gains embedded in equity method income recognized from our Asia Pacific (APAC) joint venture, which was consolidated in the fourth quarter of 2024, of approximately $0.6 million. (2) For a reconciliation of…
• FY2025 10-K: …and between DaVita Inc., a Delaware corporation, and Collaborative Care Holdings, LLC, a Delaware limited liability company, dated as of December 11, 2018, amending that certain Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., Collaborative Care Holdings, LLC, and, solely with…
• HCSG (HEALTHCARE SERVICES GROUP, INC.)
• FY2025 10-K: …some of its employees is subject to collective bargaining agreements that are negotiated by individual customer facilities and are assented by us, so as to bind us as an "employer" under the agreements. In other limited cases, we are direct parties to the agreements. We may be adversely affected by relations between…
• FY2025 10-K: …statements We have audited the accompanying consolidated balance sheets of Healthcare Services Group, Inc. (a Pennsylvania corporation) and subsidiaries (the "Company") as of December 31, 2025 and 2024, the related consolidated statements of comprehensive income, stockholders' equity, and cash flows for each of the…
• SGRY (Surgery Partners, Inc.)
• FY2025 10-K: …for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be…
• FY2025 10-K: …in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values. Variable Interest Entities The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is…
• NHC (NATIONAL HEALTHCARE CORP)
• FY2025 10-K: …Myrtle Beach Caris Healthcare - Myrtle Beach Sumter Caris Healthcare - Sumter Tennessee Athens Caris Healthcare - Athens Chattanooga Caris Healthcare - Chattanooga Columbia Caris Healthcare - Columbia Cookeville Caris Healthcare - Cookeville Clinton Caris Healthcare - Clinton Crossville Caris Healthcare - Crossville…
• FY2025 10-K: …comprehensive income - - - 1,888 - 1,888 Stock-based compensation - - 4,160 - - - 4,160 Shares sold - options exercised 232,493 1 14,268 - - - 14,269 Repurchase of common shares ( 133,151 ) - ( 13,502 ) - - - ( 13,502 ) Dividends declared to common stockholders ($ 2.42 per share) - - - ( 37,333 ) - - ( 37,333 )…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.